You are here

Kisqali

Pfizer's Ibrance, Novartis' Kisqali go to battle in England after discounts twin NICE recommendations

Fierce Pharma

Thu, 11/16/17 - 11:07 am

Novartis takes fight to Pfizer's Ibrance with new Kisqali data

Yahoo/Reuters

Wed, 11/8/17 - 10:10 am

Latecomer Verzenio stands out from Ibrance, Kisqali in launch's early days: Lilly

Fierce Pharma

Mon, 10/30/17 - 10:00 am

breast cancer. Eli Lilly

Lilly steps up to rival Pfizer, Novartis with Verzenio breast cancer approval

Fierce Pharma

Thu, 09/28/17 - 06:24 pm

Can Novartis' Kisqali beat Pfizer's market-leading Ibrance to reimbursement in England?

Fierce Pharma

Thu, 08/24/17 - 05:11 pm

New Novartis rival Kisqali hasn't slowed down Pfizer's Ibrance—at least not yet

Fierce Pharma

Mon, 08/7/17 - 01:32 pm

Lilly revs up to challenge Pfizer, Novartis in breast cancer with abemaciclib 'priority' nod

Fierce Pharma

Tue, 07/11/17 - 09:56 am

Rivals multiplying, Pfizer appeals to doctor preferences with Ibrance's latest label win

Fierce Pharma

Tue, 04/4/17 - 10:58 pm

HER-2 negative breast cancer

Will Pfizer's Growth Be Threatened by Novartis' New Cancer Drug?

Motley Fool

Wed, 03/15/17 - 09:52 pm

Watch out Pfizer, Novartis’ LEE011 bags quick OK for frontline use against breast cancer

Endpoints

Tue, 03/14/17 - 09:38 am

Pages